Interstitial lung disease associated to erlotinib treatment: a case report.

about

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors.

P2860

Q37931083-59466D53-C613-48AE-B084-395E253B2A79 Q38060727-679DFDAA-9CC5-4DF9-9C17-D0B6EC9B2352

P2860

Interstitial lung disease associated to erlotinib treatment: a case report.

Item

http://www.wikidata.org/entity/Q39488527

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Interstitial lung disease associated to erlotinib treatment: a case report.

@en

Interstitial lung disease associated to erlotinib treatment: a case report.

@nl

type

Item

label

Interstitial lung disease associated to erlotinib treatment: a case report.

@en

Interstitial lung disease associated to erlotinib treatment: a case report.

@nl

prefLabel

Interstitial lung disease associated to erlotinib treatment: a case report.

@en

Interstitial lung disease associated to erlotinib treatment: a case report.

@nl

P1476

Interstitial lung disease associated to erlotinib treatment: a case report.

@en

P2093

Carlos Rabassó

http://www.w3.org/2001/XMLSchema#string

David Castander

http://www.w3.org/2001/XMLSchema#string

Emma Muñoz

http://www.w3.org/2001/XMLSchema#string

Fernanda Bodí

http://www.w3.org/2001/XMLSchema#string

Paulina Espinosa

http://www.w3.org/2001/XMLSchema#string

Raquel Alcega

http://www.w3.org/2001/XMLSchema#string

Yolanda Del Castillo

http://www.w3.org/2001/XMLSchema#string

P2860

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.

Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.

Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee.

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.

Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

P2888

1757-1626-3-59

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1757-1626-3-59

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44637378

http://www.w3.org/2001/XMLSchema#string

P6179

1003456576

http://www.w3.org/2001/XMLSchema#string

P698

20509858

http://www.w3.org/2001/XMLSchema#string

P932

2834622

http://www.w3.org/2001/XMLSchema#string

Interstitial lung disease associated to erlotinib treatment: a case report.

about

P2860

P2860

Interstitial lung disease associated to erlotinib treatment: a case report.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P6179

P698

P932